Clinical significance of chemokine receptor antagonists

Mobilization of leukemic cells using plerixafor as part of a myeloablative preparative regimen for patients with AML undergoing allografting: assessment of safety and tolerability

(2019) Fotios V. Michelis et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Plerixafor for the Treatment of WHIM Syndrome

(2019) David H. McDermott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Maraviroc intensification modulates atherosclerotic progression in HIV suppressed patients at high cardiovascular risk. A randomized, cross-over, pilot study

(2019) Daniela Francisci et al.   Open Forum Infectious Diseases

Involvement of CXCR4 in Normal and Abnormal Development

(2019) Nanako Kawaguchi et al.   Cells

Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression via CCR5

(2019) Gen Nishikawa et al.   Cell Death & Disease

Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma

(2019) Thomas A Ollila et al.   OncoTargets and Therapy

HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation

(2019) Ravindra K. Gupta et al.   NATURE

CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy

(2019) Fedora Grande et al.   MOLECULES

Efficacy and safety of long-term Maraviroc use in a heterogeneous group of HIV-infected patients: a retrospective cohort study

(2019) J.M. Weehuizen et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Breast phyllodes tumors recruit and repolarize tumor-associated macrophages via secreting CCL5 to promote malignant progression which can be inhibited by CCR5 inhibition Therapy

(2019) Hai Hu et al.   CLINICAL CANCER RESEARCH

CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury

(2019) Mary T. Joy et al.   CELL

Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases

(2019) Yuan Cheng et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome

(2019) Yvette L. Kasamon et al.   CLINICAL CANCER RESEARCH

A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma

(2019) Salma Afifi et al.   Expert Opinion On Drug Safety

CCR5 status and metastatic progression in colorectal cancer

(2019) Meggy Suarez-Carmona et al.   OncoImmunology

Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders

(2019) Laura Fantuzzi et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors

(2019) Toshihiko Doi et al.   CLINICAL CANCER RESEARCH

GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma

(2019) Zachary D Crees et al.   Future Oncology

The CXCR4–CXCL12-Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro

(2019) Katrin Pansy et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pharmacogenomics of GPCR Drug Targets

(2018) Alexander S. Hauser et al.   CELL

Improving maraviroc oral bioavailability by formation of solid drug nanoparticles

(2018) Alison C. Savage et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Towards a Maraviroc Long-Acting Injectable Nanoformulation

(2018) Lee M. Tatham et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis

(2018) Frank Tacke   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A guide to chemokines and their receptors

(2018) Catherine E. Hughes et al.   FEBS Journal

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia

(2018) Gail J Roboz et al.   HAEMATOLOGICA

Hematopoietic stem cell mobilization with plerixafor in sickle cell disease

(2018) Matthew M. Hsieh et al.   HAEMATOLOGICA

Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion

(2018) Chantal Lagresle-Peyrou et al.   HAEMATOLOGICA

Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis

(2018) Oliver Krenkel et al.   HEPATOLOGY

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

(2018) Scott L. Friedman et al.   HEPATOLOGY

Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV Following Dual CCR2 and CCR5 Antagonism

(2018) Michelle L. D’Antoni et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise

(2018) Palak J Trivedi et al.   Journal of Crohns & Colitis

Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice

(2018) Maria Eugenia Guicciardi et al.   JOURNAL OF HEPATOLOGY

Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4+ T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy

(2018) Nadia Madrid-Elena et al.   JOURNAL OF VIROLOGY

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial

(2018) Sonia Pernas et al.   LANCET ONCOLOGY

Mogamulizumab (Anti-CCR4) in HTLV-1–Associated Myelopathy

(2018) Tomoo Sato et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1

(2018) Carlo Giaquinto et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

The return of PRO 140, a CCR5-directed mAb

(2018) Melanie A. Thompson   Current Opinion in HIV and AIDS

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia

(2018) Gail J Roboz et al.   HAEMATOLOGICA

Hematopoietic stem cell mobilization with plerixafor in sickle cell disease

(2018) Matthew M. Hsieh et al.   HAEMATOLOGICA

Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion

(2018) Chantal Lagresle-Peyrou et al.   HAEMATOLOGICA

Autologous stem cell transplantation outcomes for relapsed metastatic germ cell tumors in the modern era

(2018) Anis A. Hamid et al.   Clinical Genitourinary Cancer

Pharmacological inhibition of CCR2/5 signaling prevents and reverses alcohol-induced liver damage, steatosis and inflammation in mice

(2018) Aditya Ambade et al.   HEPATOLOGY

Pyrrolone derivatives as intracellular allosteric modulators for chemokine receptors: Selective and dual-targeting inhibitors of CC Chemokine Receptors 1 and 2

(2018) Natalia Veneranda Ortiz Zacarías et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

(2018) Youn H Kim et al.   LANCET ONCOLOGY

CCR4 Antagonists Inhibit Treg Trafficking into the Tumor Microenvironment

(2018) John M. Ketcham et al.   ACS Medicinal Chemistry Letters

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth

(2018) Naike Casagrande et al.   HAEMATOLOGICA

Mogamulizumab versus investigator choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma

(2018) Adrienne A. Phillips et al.   HAEMATOLOGICA

WHIM syndrome: Immunopathogenesis, treatment and cure strategies

(2018) David H. McDermott et al.   IMMUNOLOGICAL REVIEWS

Adaptive Immunodeficiency in WHIM Syndrome

(2018) Shamik Majumdar et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Structural basis of coreceptor recognition by HIV-1 envelope spike

(2018) Md Munan Shaik et al.   NATURE

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials

(2018) Marilyn Lewis et al.   PLoS One

Biased antagonism of CXCR4 avoids antagonist tolerance

(2018) Ben Hitchinson et al.   Science Signaling

Mycosis Fungoides and Sézary Syndrome

(2018) Cecilia Larocca et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM

(2018) Ian McGowan et al.   AIDS

Pharmacogenetic considerations for HIV treatment in different ethnicities: an update

(2017) M. Neary et al.   Expert Opinion on Drug Metabolism & Toxicology

Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study

(2017) SL Pett et al.   HIV MEDICINE

Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV

(2017) Yi Zheng et al.   IMMUNITY

Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial)

(2017) Ana Milinkovic et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Structural Analysis of Chemokine Receptor–Ligand Interactions

(2017) Marta Arimont et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial

(2017) Darja Karpova et al.   Journal of Translational Medicine

The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression

(2017) M Abraham et al.   LEUKEMIA

A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Co

(2017) Todd M. Cooper et al.   PEDIATRIC BLOOD & CANCER

Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non−Hodgkin's lymphoma: a randomized Phase 3 study

(2017) Jun Zhu et al.   TRANSFUSION

Beyond Chemoattraction: Multifunctionality of Chemokine Receptors in Leukocytes

(2017) Pilar López-Cotarelo et al.   TRENDS IN IMMUNOLOGY

A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia

(2017) G L Uy et al.   Blood Cancer Journal

Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases

(2017) Helen Ha et al.   Theranostics

Up-regulation of chemokine receptor CCR4 is associated with Human Hepatocellular Carcinoma malignant behavior

(2017) Xi Cheng et al.   Scientific Reports

Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates

(2016) Carolina Herrera et al.   AIDS

Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients

(2016) Niels Halama et al.   CANCER CELL

Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study

(2016) Sarah Lilian Pett et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment

(2016) E Lefebvre et al.   CTS-Clinical and Translational Science

Plerixafor for stem cell mobilization

(2016) Yavuz M. Bilgin et al.   CURRENT OPINION IN HEMATOLOGY

Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists

(2016) Yi Zheng et al.   NATURE

CCR5 blockade for neuroinflammatory diseases — beyond control of HIV

(2016) Guillaume Martin-Blondel et al.   Nature Reviews Neurology

Maraviroc reduces neuropathic pain through polarization of microglia and astroglia – Evidence from in vivo and in vitro studies

(2016) Anna Piotrowska et al.   NEUROPHARMACOLOGY

HIV-1 adaptation to low levels of CCR5 results in V3 and V2 loop changes that increase envelope pathogenicity, CCR5 affinity and decrease susceptibility to Maraviroc

(2016) Himanshu Garg et al.   VIROLOGY

CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress

(2016) Yanyan Zhang et al.   Scientific Reports

Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients

(2016) Stefania Piconi et al.   Scientific Reports

Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial

(2016) Sergio Serrano-Villar et al.   PLoS Pathogens

Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis

(2016) Amit C Achhra et al.   Lancet HIV

Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy

(2015) G. Karponi et al.   BLOOD

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

(2015) M. Duvic et al.   BLOOD

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan–fludarabine conditioning for allogeneic stem cell transplantation

(2015) M Konopleva et al.   BONE MARROW TRANSPLANTATION

Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study

(2015) Takashi Ishida et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients

(2015) K. Kurose et al.   CLINICAL CANCER RESEARCH

“Chemokine receptors as therapeutic targets: Why aren’t there more drugs?”

(2015) Roberto Solari et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents

(2015) Juergen K. Rockstroh et al.   HIV CLINICAL TRIALS

A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity

(2015) Javier Garcia-Perez et al.   Retrovirology

A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor

(2014) D. H. McDermott et al.   BLOOD

Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome

(2014) X. Ni et al.   CLINICAL CANCER RESEARCH

Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition

(2014) George Panos et al.   CRITICAL REVIEWS IN MICROBIOLOGY

Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting

(2014) J Macías et al.   HIV MEDICINE

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

(2014) Michinori Ogura et al.   JOURNAL OF CLINICAL ONCOLOGY

CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4

(2014) Takashi Nagasawa   JOURNAL OF MOLECULAR MEDICINE-JMM

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1

(2013) David A. Cooper et al.   AIDS

Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy

(2013) S K Kumar et al.   BONE MARROW TRANSPLANTATION

Structure-Based Development of Antagonists for Chemokine Receptor CXCR4

(2013) Chongqian Zhang et al.   Current Computer-Aided Drug Design

Pharmacokinetics, Safety, and Tolerability of Maraviroc in HIV-Negative Subjects with Impaired Renal Function

(2013) Manoli Vourvahis et al.   HIV CLINICAL TRIALS

Lack of Prophylactic Efficacy of Oral Maraviroc in Macaques despite High Drug Concentrations in Rectal Tissues

(2013) I. Massud et al.   JOURNAL OF VIROLOGY

Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex

(2013) Q. Tan et al.   SCIENCE

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

(2012) G. L. Uy et al.   BLOOD

Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin’s lymphoma and multiple myeloma: results from the expanded access program

(2012) P Shaughnessy et al.   BONE MARROW TRANSPLANTATION

Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumors

(2012) M E Horwitz et al.   BONE MARROW TRANSPLANTATION

A review on CXCR4/CXCL12 axis in oncology: No place to hide

(2012) Urszula M. Domanska et al.   EUROPEAN JOURNAL OF CANCER

Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial

(2012) N. Russell et al.   HAEMATOLOGICA

The Chemokine Superfamily Revisited

(2012) Albert Zlotnik et al.   IMMUNITY

Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study

(2012) Takashi Ishida et al.   JOURNAL OF CLINICAL ONCOLOGY

HIV-1 Resistance to Maraviroc Conferred by a CD4 Binding Site Mutation in the Envelope Glycoprotein gp120

(2012) A. N. Ratcliff et al.   JOURNAL OF VIROLOGY

CCR10 and its ligands in regulation of epithelial immunity and diseases

(2012) Na Xiong et al.   Protein & Cell

Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide

(2011) Florent Malard et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Plerixafor

(2011) Gillian M. Keating   DRUGS

Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and Rectal Tissue of Healthy HIV-Negative Men

(2011) Kevin C. Brown et al.   JOURNAL OF INFECTIOUS DISEASES

Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience

(2011) Luca Arcaini et al.   LEUKEMIA RESEARCH

Hematopoietic Stem Cell Mobilization for Gene Therapy of Adult Patients With Severe β-Thalassemia: Results of Clinical Trials Using G-CSF or Plerixafor in Splenectomized and Nonsplenectomized Subjects

(2011) Evangelia Yannaki et al.   MOLECULAR THERAPY

Evidence for the cure of HIV infection by CCR5 32/ 32 stem cell transplantation

(2010) K. Allers et al.   BLOOD

Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients

(2010) S Kobold et al.   BONE MARROW TRANSPLANTATION

Maraviroc

(2010) Caroline M. Perry   DRUGS

Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2

(2010) W David Hardy et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients

(2010) E. Seclen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma

(2010) Kazuhito Yamamoto et al.   JOURNAL OF CLINICAL ONCOLOGY

Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection

(2010) David A. Cooper et al.   JOURNAL OF INFECTIOUS DISEASES

Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experienc

(2010) Nina Worel et al.   TRANSFUSION

The Monoclonal CCR5 Antibody PRO-140: The Promise of Once-Weekly HIV Therapy

(2010) Allan R. Tenorio   Current HIV/AIDS Reports

Treatment with Plerixafor in non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF: Implications for the Heavily Pretreated Patient

(2009) Patrick Stiff et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Pharmacokinetics and Pharmacodynamics of Plerixafor in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma

(2009) Douglas A. Stewart et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A Pharmacokinetic Study of Plerixafor in Subjects with Varying Degrees of Renal Impairment

(2009) Ronald MacFarland et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

(2009) J. F. DiPersio et al.   BLOOD

Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients

(2009) S Fruehauf et al.   BONE MARROW TRANSPLANTATION

Plerixafor

(2009) Antona J. Wagstaff   DRUGS

Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women

(2009) Julie B Dumond et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma

(2009) John F. DiPersio et al.   JOURNAL OF CLINICAL ONCOLOGY

The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation

(2009) M Abraham et al.   LEUKEMIA

A Phase II Study of Plerixafor (AMD3100) plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization in Patients with Hodgkin Lymphoma

(2008) Amanda Cashen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction

(2008) S. M. Devine et al.   BLOOD

Maraviroc:in vitroassessment of drug-drug interaction potential

(2008) Ruth Hyland et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects

(2008) Samantha Abel et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Chemokine receptor antagonists: overcoming developmental hurdles

(2008) Richard Horuk   NATURE REVIEWS DRUG DISCOVERY

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

(2008) Gerd Fätkenheuer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

(2008) Roy M. Gulick et al.   NEW ENGLAND JOURNAL OF MEDICINE